Back to results
US 2023/0406948 A1Published application
Anti-cd40 antibodies and methods of use
AssigneeApexigen, Inc.
InventorsYongke ZHANG, Guo-Liang YU, Weimin ZHU
Life of this patent
Estimating the term…
Abstract
The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.
Claims13
1-23. (canceled)
A humanized monoclonal antibody that binds to CD40 and is a CD40 agonist, comprising:
- (i) a heavy chain variable region comprising the VHCDR1 region set forth in SEQ ID NO:3, the VHCDR2 region set forth in SEQ ID NO:4, and the VHCDR3 region set forth SEQ ID NO:5;
- (ii) a light chain variable region comprising the VLCDR1 region set forth in SEQ ID NO:6, the VLCDR2 region set forth in SEQ ID NO:7, and the VLCDR3 region set forth in SEQ ID NO:
- 8;
- and
- (iii) a human IgG1 heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:
- 195.
3 more elements
Dependencies are inferred from the claim text.